Key statistics
On Monday, Autolus Therapeutics PLC (6A3A:MUN) closed at 1.19, 14.42% above the 52 week low of 1.04 set on Apr 11, 2025.
52-week range
| Open | 1.19 |
|---|---|
| High | 1.19 |
| Low | 1.19 |
| Bid | 1.16 |
| Offer | 1.21 |
| Previous close | 1.19 |
| Average volume | 1.54k |
|---|---|
| Shares outstanding | 266.14m |
| Free float | 8.82m |
| P/E (TTM) | -- |
| Market cap | 372.60m USD |
| EPS (TTM) | -0.8447 USD |
Data delayed at least 15 minutes, as of Feb 16 2026 07:00 GMT.
More ▼
- Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026
- Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform
- Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025
- Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
- Autolus Therapeutics Appoints Ryan Richardson to Board of Directors
- NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹
- Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
- Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
- Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025
More ▼
